Contains Nonbinding Recommendations

Draft Guidance on Temozolomide

This draft guidance, once finalized, will represent the Food and Drug Administration's (FDA's) current thinking on this topic. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. You can use an alternative approach if the approach satisfies the requirements of the applicable statutes and regulations. If you want to discuss an alternative approach, contact the Office of Generic Drugs.

Active ingredient: Temozolomide

Form/Route: Capsules/Oral

Recommended studies: 1 study

Type of study: Fasting
Design: Single-dose, two way crossover *in-vivo*
Strength: 250 mg
Subjects: Cancer patients undergoing treatment with temozolomide or former cancer patients who are in remission if insufficient cancer patients can be recruited.
Additional comments: If cancer patients are enrolled, they should receive individualized regimens using multiples of the 250 mg strength. If former cancer patients who are in remission are enrolled, each former patient should receive a single dose of 250 mg. If cancer patients undergoing temozolomide treatment are used, please conduct the BE study dosing and blood sampling on the first day of a treatment cycle. Submission of an Investigational New Drug Application (IND) is required prior to conducting a bioequivalence study for a cytotoxic drug product such as temozolomide (See 21 C.F.R § 320.31).

Analytes to measure (in appropriate biological fluid): Temozolomide in plasma

Bioequivalence based on (90% CI): Temozolomide

Waiver request of in-vivo testing: 5 mg, 20mg, 100 mg, 140 mg and 180 mg based on (i) acceptable bioequivalence study on the 250 mg strengths, (ii) acceptable dissolution testing of all strengths and (iii) proportionally similar across all strengths.

Dissolution test method and sampling times:

Please note that a **Dissolution Methods Database** is available to the public at the OGD website at http://www.fda.gov/cder/ogd/index.htm. Please find the dissolution information for this product at this website. Please conduct comparative dissolution testing on 12 dosage units each of all strengths of the test and reference products. Specifications will be determined upon review of the application.